Vardenafil (Levitra/Staxyn) Month-by-Month: Real Results in the First 3 Months

What Vardenafil Is and How It Works

Vardenafil belongs to the PDE5 inhibitor class, the same pharmacological family as sildenafil (Viagra) and tadalafil (Cialis). It works by blocking phosphodiesterase type 5 in cavernous smooth muscle, which allows cyclic GMP to accumulate, smooth muscle to relax, and blood to fill the corpora cavernosa during sexual stimulation. Without stimulation, the drug does nothing. That point trips up first-time users more than almost any other.

Mechanism at the Receptor Level

PDE5 is expressed primarily in penile smooth muscle, pulmonary vasculature, and platelets. Vardenafil's IC50 for PDE5 is approximately 0.7 nM, making it roughly 10-fold more potent than sildenafil at the enzyme level, though clinical head-to-head comparisons show more modest real-world differences. The FDA label for Levitra documents selectivity ratios exceeding 1,000-fold for PDE5 over PDE1, PDE2, and PDE4.

Formulation Differences: Levitra vs. Staxyn

Levitra is a film-coated tablet taken with or without food. Staxyn is an orally disintegrating tablet placed on the tongue, absorbed through the oral mucosa in part, which may shorten time to onset slightly in some men. The FDA approved Staxyn in June 2010 specifically to offer a water-free option. FDA prescribing information for Staxyn specifies that Staxyn is not bioequivalent to Levitra tablet on a mg-for-mg basis, so doses should not be freely substituted without physician guidance.

Month 1: First Dose Through Week 4

What Happens on Dose 1

The first month is primarily about establishing whether vardenafil works for an individual man and at which dose. Most prescribers start at 10 mg taken 30 to 60 minutes before sexual activity. In a pooled Phase III analysis of 2,203 men with erectile dysfunction of varying etiologies, vardenafil 10 mg produced a statistically significant improvement in erectile function domain scores of the International Index of Erectile Function (IIEF-EF) versus placebo as early as the first evaluated time point. Goldstein et al., Urology 2003 reported that 65% of attempts resulted in successful vaginal penetration with vardenafil 10 mg versus 33% with placebo (P<0.001).

Real-world accounts on Drugs.com and Reddit's r/erectiledysfunction mirror these numbers. A common thread: men who take vardenafil expecting it to cause a spontaneous erection are disappointed on dose 1. Those who understand stimulation is required and who use the drug in low-stress settings report a noticeably firmer erection with less effort than baseline.

Side Effects in the First Two Weeks

Early side effects peak around days 1 through 14, before physiological tolerance to vasodilatory effects develops. The FDA label documents headache in approximately 15% of men, flushing in 11%, and rhinitis in 9% at the 10 mg dose. Hatzichristou et al., BJU Int 2004 confirmed this side-effect profile in a 12-week European trial (N=601), noting that adverse events were dose-dependent and largely mild to moderate.

Men on Reddit frequently describe the headache as "behind the eyes" and lasting 2 to 3 hours. Taking 600 mg ibuprofen 30 minutes before vardenafil is a common lay strategy. Physicians generally consider it acceptable unless the patient has gastrointestinal contraindications, but this should always be cleared with the prescriber first.

Dose Adjustment in Month 1

If 10 mg produces inadequate rigidity with acceptable tolerability, the dose may be increased to 20 mg. If headache or flushing is limiting, a reduction to 5 mg is appropriate. The Levitra prescribing information states the maximum recommended dose is 20 mg once daily and that use more than once per day is not recommended. Men with hepatic impairment (Child-Pugh B) should not exceed 10 mg; the starting dose for men over 65 is 5 mg.

A key clinical reality in month 1: roughly 25 to 35% of men do not respond adequately to the starting 10 mg dose and either need a dose increase or a different PDE5 inhibitor. Porst et al., Eur Urol 2001 showed dose-response separation between 5, 10, and 20 mg in a 12-week placebo-controlled study (N=580), with 20 mg producing IIEF-EF domain scores of 23.9 versus 14.0 for placebo (P<0.001).

Month 2: Dialing In the Protocol

By week 5 through week 8, most men have had 4 to 10 dosing occasions and have a clearer sense of what vardenafil does for them specifically. This is the calibration phase.

Timing Optimization

Vardenafil's half-life of 4 to 5 hours means that timing matters more than with tadalafil (half-life 17.5 hours). Men who took their first doses 30 minutes before activity and found the drug "not yet working" sometimes shift to 45 to 60 minutes. High-fat meals delay peak plasma concentration (Tmax) by approximately 60 minutes and reduce Cmax by 18 to 20%, per the FDA label. Switching to a light pre-meal or a fasted state often resolves what men assume is a drug failure.

Psychological Factors and Performance Anxiety

Month 2 is where psychological variables become more visible. Men with significant performance anxiety may have responded inconsistently in month 1. Rosen et al., Eur Urol 2007 found that psychological distress at baseline moderated PDE5-inhibitor response, with men scoring high on the Erection Hardness Score who also had high anxiety scores showing smaller gains than men with low anxiety. Cognitive behavioral approaches alongside pharmacotherapy improve outcomes, though that combination requires a mental health referral beyond just an ED prescription.

What Patient Reports Show at 8 Weeks

Synthesized accounts from Drugs.com (average rating 7.4/10 across 312 reviews as of mid-2025) show a consistent pattern: men who reach 8 weeks with the right dose report high satisfaction with spontaneity and sensation compared to their pre-treatment baseline. Negative reviews cluster around two complaints: headache that persists beyond week 4, and cost (generic vardenafil without insurance averages $8 to $12 per tablet at major pharmacy chains, compared to $1 to $3 for generic sildenafil).

Shabsigh et al., BJU Int 2004 evaluated partner satisfaction alongside patient satisfaction in a 26-week trial. At week 12, 76% of partners reported improved sexual satisfaction with vardenafil 20 mg versus 48% with placebo (P<0.001), suggesting that the drug's effect extends meaningfully to relationship quality by the midpoint of the standard trial period.

When to Consider Switching

If a man has tried both 10 mg and 20 mg of vardenafil with at least three dosing occasions each under optimized conditions (light meal, low anxiety, adequate stimulation, correct timing) and IIEF-EF domain scores remain below 17 (the clinical threshold for at least moderate erectile function), switching to tadalafil or sildenafil is reasonable. Corona et al., J Sex Med 2012 meta-analyzed 82 randomized controlled trials (N=24,323) and found no significant difference in efficacy between PDE5 inhibitors at the class level, but individual responder patterns do differ.

Month 3: Stabilization and Long-Term Projection

Efficacy Plateau and Sustained Response

By weeks 9 through 12, the pattern of response is generally stable. The clinical trial that most closely mirrors a real-world 3-month experience is the 12-week Phase III study by Hellstrom et al., Urology 2002 (N=805), which showed that men on vardenafil 20 mg achieved a mean IIEF-EF domain score of 24.0 at endpoint versus 13.6 for placebo (P<0.001), with 80% of attempts at penetration being successful at the final visit. The number-needed-to-treat to achieve one additional successful intercourse attempt versus placebo was approximately 2.

Tolerance: Does Vardenafil Stop Working?

Tachyphylaxis (pharmacological tolerance) is not a recognized feature of PDE5 inhibitor therapy in clinical trials. Men who report that vardenafil "stopped working" at month 3 most often fall into one of three groups: those who have developed new comorbidities (uncontrolled hypertension, worsening diabetes), those whose testosterone has dropped significantly (hypogonadism reduces PDE5-inhibitor response), or those using the drug incorrectly. Kendirci et al., Curr Opin Urol 2006 reviewed this question specifically and found no pharmacodynamic evidence for true tolerance; apparent loss of efficacy nearly always had an identifiable clinical cause.

A total testosterone level below 300 ng/dL may explain poor PDE5-inhibitor response in men whose ED was otherwise unexplained. Isidori et al., Eur Urol 2014 showed in a randomized trial (N=140) that adding testosterone replacement to a PDE5 inhibitor in hypogonadal men who had failed PDE5 inhibitor monotherapy restored response in 63% of cases.

Side-Effect Trajectory at 12 Weeks

Most vasodilatory side effects diminish by month 3. Porst et al., Eur Urol 2001 showed that headache rates dropped from approximately 13% in weeks 1 to 4 to 8% in weeks 9 to 12 in the 20 mg group, suggesting some degree of vascular adaptation. Men who still have limiting headaches at 3 months may benefit from switching to tadalafil 5 mg daily, which maintains lower peak plasma concentrations and is associated with lower headache rates per Porst et al., Eur Urol 2006.

Cardiovascular Safety Through Month 3

The cardiovascular safety of vardenafil is well-characterized. Mittleman et al., Am J Cardiol 2006 reviewed cardiovascular event rates across Phase II and Phase III vardenafil trials (N=4,430 total participants) and found no increase in myocardial infarction rates compared to age-matched background rates. The absolute contraindication remains concurrent nitrate use. Men on alpha-blockers should use no less than a 6-hour separation between alpha-blocker and vardenafil doses, per the FDA Levitra label, to avoid symptomatic hypotension.

The HealthRX 3-Month Vardenafil Response Framework

Clinicians on the HealthRX medical team use a structured 3-checkpoint protocol to evaluate and adjust vardenafil therapy. This framework consolidates trial evidence, FDA labeling, and the clinical patterns seen across our patient population into a decision tool that providers can apply at each monthly check-in.

Checkpoint 1 (End of Month 1, ~Week 4)

• Confirm the patient understands stimulation is required.
• Document IIEF-EF domain score (target: score of 17 or above indicates at least moderate function).
• If score is below 17 at 10 mg with correct technique, increase to 20 mg.
• If side effects are limiting at 10 mg, reduce to 5 mg and reassess in 4 weeks.
• Check for new nitrate prescriptions, ketoconazole, or ritonavir (dose cap at 2.5 mg required with strong CYP3A4 inhibitors, per FDA label).

Checkpoint 2 (End of Month 2, ~Week 8)

• Review timing and food interactions.
• If response is inconsistent, screen for performance anxiety using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7); scores of 10 or above on either warrant a mental health co-management discussion.
• Check fasting testosterone. Levels below 300 ng/dL should prompt endocrine evaluation per Endocrine Society Clinical Practice Guidelines (Bhasin et al., J Clin Endocrinol Metab 2018).
• If 20 mg produces IIEF-EF below 17 with correct technique, consider switching to sildenafil or tadalafil before investing a third month.

Checkpoint 3 (End of Month 3, ~Week 12)

• Re-administer IIEF-EF. A score of 22 to 25 indicates good function; above 25 indicates no dysfunction by clinical definition.
• Reassess blood pressure (vardenafil reduces mean systolic BP by 5 to 6 mmHg at peak in normotensive men, per Webb et al., J Am Coll Cardiol 1999, so ongoing antihypertensive adjustments may be needed).
• Discuss whether on-demand dosing (current approach) or tadalafil 5 mg daily better fits the patient's sexual activity frequency.
• If response is satisfactory, document and schedule 6-month review.

Drug Interactions and Safety Signals Worth Knowing

Vardenafil is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C9. The FDA label specifies that ritonavir increases vardenafil AUC by 49-fold, making co-administration contraindicated. Ketoconazole 400 mg daily increases vardenafil AUC by 10-fold, requiring a maximum dose of 2.5 mg per 72 hours. These are not theoretical interactions; they carry real hypotension risk.

Fung et al., Am J Cardiol 2004 evaluated the interaction between vardenafil and alpha-blockers (specifically tamsulosin and terazosin) in men with benign prostatic hyperplasia. Terazosin plus vardenafil produced clinically significant blood pressure drops (systolic decreases exceeding 30 mmHg in some subjects), while the tamsulosin interaction was more modest. Men on terazosin should use vardenafil only with a confirmed 6-hour separation and ideally under physician supervision for the first dose.

Rare but serious: non-arteritic anterior ischemic optic neuropathy (NAION) has been reported in post-marketing data for all PDE5 inhibitors. McGwin et al., Br J Ophthalmol 2006 found an association between PDE5 inhibitor use and NAION (OR 2.15, 95% CI 1.06 to 4.37), though causality remains unestablished and the absolute risk is very low. Men with a prior NAION episode in one eye should discuss the risk before continuing any PDE5 inhibitor.

Who Responds Best (and Who Responds Least)

Strong Predictors of Good Response

Men with psychogenic or mixed-etiology ED, lower severity at baseline (IIEF-EF 11 to 16), normal testosterone, and no major vascular comorbidities show the strongest response to vardenafil. Montorsi et al., Eur Urol 2004 identified baseline IIEF-EF score and etiology as the two most powerful predictors of PDE5-inhibitor response in a pooled analysis of 2,430 men, with men with psychogenic ED achieving success rates exceeding 85%.

Harder-to-Treat Populations

Men with diabetes-related ED face lower absolute response rates. Rendell et al., JAMA 1999 (N=268, sildenafil study, directly informative for class-level expectations) showed that men with type 1 or type 2 diabetes responded at rates approximately 20 percentage points lower than non-diabetic men. Vardenafil-specific diabetic data from Goldstein et al., Diabetes Care 2003 (N=452) showed 57% of men with type 2 diabetes achieved successful intercourse at vardenafil 20 mg versus 13% with placebo, confirming meaningful benefit but a lower ceiling than in non-diabetic populations.

Post-radical prostatectomy ED remains the hardest category. Brock et al., Urology 2003 (N=440 bilateral nerve-sparing prostatectomy patients) showed vardenafil 20 mg produced 71% successful penetration attempts versus 29% for placebo, a clinically significant difference, but absolute success rates depended heavily on nerve preservation status.

Comparing Real-World Accounts to Trial Data

Reddit and Forum Patterns

The dominant themes across r/erectiledysfunction and r/menshealth threads mentioning vardenafil align closely with trial data in some areas and diverge in others. Men consistently report faster subjective onset than with sildenafil, which matches vardenafil's earlier Tmax in some pharmacokinetic studies. The complaint about cost is nearly universal in US-based posts, since generic vardenafil received FDA approval significantly later than generic sildenafil (which became available in 2017 at prices under $1 per dose from some manufacturers).

Where Forum Reports Diverge From Trials

Forum users frequently describe an interaction between alcohol and vardenafil efficacy that trial protocols do not capture, since most Phase III studies prohibited alcohol within 4 hours of dosing. The FDA label notes that alcohol (0.5 g/kg) given with vardenafil 20 mg augments the mean maximum blood pressure decrease by approximately 4 mmHg beyond either agent alone. Heavy alcohol consumption (more than 3 standard drinks) reliably impairs erectile function independent of any medication by suppressing nitric oxide release; Fahrner EM, Drug Alcohol Depend 1987 documented this effect at blood alcohol levels as low as 40 mg/dL.

Forum users also report that food timing matters less than they expected, which is broadly consistent with the pharmacokinetic data: high-fat meals delay but do not eliminate effect, and many men compensate by simply dosing 90 minutes before activity rather than 30 to 60 minutes.